ComputerWorld AI·
It was the best of trends, it was the worst of trends. It was the epoch of artificial intelligence, it was the epoch of artificial inflation. I’m truly excited to be alive at a time when AI, formerly the stuff of science fiction, is now an everyday reality and promising so many benefits to humankind. AI is accelerating drug discovery, slashing the cost of protein folding research, diagnosing cancers earlier than human radiologists can, automating the drudgery out of nearly every white-collar job, translating speech across hundreds of languages in real time, and giving the blind a way to see the world through a camera. AI is giving us all this and so much more. But no amount of techno-optimism can hide the fact that AI is making just about everything more expensive. While the AI trend is making a tiny number of rich people even richer, the public at large is paying the price through rapidly rising prices; it represents a transfer of wealth from the have-nots to the haves. AI is a
Read full articleAI-driven optimization in drug synthesis accelerates R&D timelines, potentially reducing costs and expediting market entry for pharmaceuticals. The post GPT-5.4 improves Chan-Lam coupling yields in drug discovery appeared first on Crypto Briefing.
Pramaana will focus on highly sensitive verticals like law, drug discovery, and tax preparation — where errors can be costly and reliability is at a premium.
The nonprofit consortium is advancing open-source foundation models and software infrastructure for biology and drug discovery. BERKELEY, Calif., June 9, 2026 — OpenFold Consortium, an open science initiative advancing open-source AI […] The post OpenFold Adds 11 Members to Expand Open-Source AI for Drug Discovery appeared first on AIwire.
SAN FRANCISCO, June 4, 2026 — Causaly has announced a collaboration with Microsoft at Microsoft Build 2026 that brings scientific computation and scientific interpretation together into a single, evidence-grounded workflow […] The post Causaly and Microsoft Integrate Scientific Reasoning and Analytics for Drug Discovery appeared first on AIwire.
Artificial intelligence is restructuring medicine from the exam room to the lab bench. The companies doing it most consequentially are not just digitizing old workflows — they are replacing the underlying logic of how care gets documented, how drugs get discovered, how patients move through the system, and how clinicians access knowledge. From cardiothoracic imaging to whole-brain […]
Biohub's AI toolkit democratizes drug discovery, enabling smaller biotech firms to innovate and compete, potentially transforming the industry. The post Biohub unveils AI world model for protein biology, aiming to reshape drug discovery appeared first on Crypto Briefing.
Bristol Myers' AI integration could revolutionize pharmaceutical processes, enhancing efficiency and safety while setting new industry standards. The post Bristol Myers deploys Anthropic’s Claude AI to accelerate drug discovery appeared first on Crypto Briefing.
SandboxAQ, the Alphabet spinout chaired by former Google CEO Eric Schmidt, has partnered with Anthropic to embed its large quantitative models directly into Claude, making powerful drug discovery and materials science tools accessible through a natural language interface for the first time. The company’s proprietary LQMs are physics-grounded AI models trained on real-world lab data […]
